Srdan Verstovsek, MD, PhD, discusses the use of interferon in rare blood diseases.
Stephanie L. Graff, MD, discusses data surrounding escalation and de-escalation in patients with early-stage, hormone receptor–positive breast cancer.
Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.
Combining ibrutinib with the CDK4/6 inhibitor palbociclib appeared to be well tolerated and active in patients with previously treated mantle cell lymphoma.
The FDA has granted a priority review to a supplemental new drug application for ivosidenib for the frontline treatment of patients IDH1-mutant acute myeloid leukemia who are ineligible for standard chemotherapy.
The 4-drug combination of rituximab, bendamustine, bortezomib, and dexamethasone was found to improve progression-free survival and demonstrated a tolerable safety profile as frontline treatment for patients with mantle cell lymphoma who are ≥65 years.
The combination of pembrolizumab plus best supportive care for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy did not improve progression-free or overall survival compared with placebo plus best supportive care alone, missing the coprimary endpoints of the KEYNOTE-240 trial.
Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.
The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for patients with advanced small cell lung cancer whose disease has progressed following ≥2 prior lines of therapy.
Under the current administration, a policy implemented at the turn of the year could have far-reaching effects on the healthcare reform effort.